Tag: Pharma
BSV partners Indian Institute of Science for research on next-gen snakebite...
Supports research of Antibodies & Antivenom development at the IISc Evolutionary Venomics Laboratory facility
AiMeD urges PM for a separate department for medical devices
AiMeD on behalf of the Indian medical devices industry writes to PM Narendra Modi to change the name of Department of Pharmaceuticals to Department of Pharmaceuticals & Medical Devices
Baxter Pharmaceuticals India celebrates 5 years of operations in Ahmedabad
The Baxter Ahmedabad facility is a cutting-edge generic injectables manufacturing facility that produces essential generic medicines
Merck India’s 3rd Annual Pharma Forum 2022 to be held in...
The event scheduled on 10th August is focused on shaping the next gen processing of pharma manufacturing
Sun Pharma chairman, Israel Makov to retire on completion of term
Leading the company’s global expansion, he guided the acquisition of Ranbaxy in 2014, making Sun Pharma the leader in the Indian pharmaceutical market and a strong player globally
Zenara Pharma gets CDSCO nod to manufacture & sell generic of...
This approval by the CDSCO has been granted under the emergency authorization route considering the unmet medical need in COVID-19 for an effective and affordable therapy for the patients
Pricing pressures & regulatory scrutiny persist in US generics pharma industry:...
Some major Indian pharmaceutical companies reported sizeable impairment losses and also announced discontinuation of some products or segments due to lower earnings potential
US$ 10 billion oncology research to provide tailwinds to gene therapy...
Rising quest to search for breakthroughs in medical treatments have been fueling demand for gene therapy of various grades
Merck opens Microbiology Application Lab in Jigani, Bengaluru
Supports capability built-up in microbial quality control in Pharma, and biopharma industry Merck invests €200,000 in the infrastructure of the new lab at Jigani
Indian pharma companies to grow by 6-7% in FY2023: ICRA study
Headwinds related to pricing pressures in the US generics market and rising raw material costs will result in contraction of sample set profit margins in FY2023